Skip to NavigationSkip to content

Gilead’s drug boosted by positive Phase II trials and aims to move forward

Published on 21/10/16 at 09:51am

Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The drug treats fatty liver disease, which is more commonly known as NASH (non-alcoholic steatohepatitis. The drug was tested alone and alongside Gilead’s experimental anti-fibrotic drug simtuzumab. The treatment was found to reduce liver scarring in the mid-stage trial.

The results showed that 43% of patients saw improvement on an 18mg of selonsertib, with only 3% progressing to cirrhosis. The results were found not to differ whether anti-fibrotic drug simtuzumab was introduced or not. Selonsertib was administered daily via an oral dose. Due to the positive results, Phase III clinical trials are already being planned.

“We are committed to advancing our pipeline of investigational molecules that separately target metabolic dysfunction, inflammation and/or fibrosis associated with NASH,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “We are encouraged by these data demonstrating the anti-fibrotic effect of GS-4997 in patients with NASH after only 24 weeks of treatment, and look forward to sharing the complete results with the hepatology community. Additionally, pending discussions with regulatory agencies, we plan to initiate a Phase 3 clinical trial program of GS-4997 in patients with NASH.”

The drug was also being tested in Phase II to ascertain whether it could be an effective treatment for pulmonary arterial hypertension and diabetic kidney disease. However, the data from their Phase II trials saw the drug fail to reach the primary endpoints for these indications.

 Ben Hargreaves

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches